All
Increased Abdominal Fat Associated With Higher Cancer Risk
September 12th 2017A higher percentage of body fat – specifically fat in the abdominal area – was associated with an increased risk of certain cancers for postmenopausal women, according to a recent study presented at the 2017 European Society of Medical Oncology (ESMO) Congress in Madrid, Spain.
BRCA Gene Mutation May Harm Fertility Preservation in Women With Breast Cancer
September 10th 2017Women with breast cancer who are positive for the BRCA gene mutation may be more likely to encounter difficulty with fertility preservation compared to women with breast cancer who have tested negative for the BRCA mutation.
Careers of Young Survivors Can be Disrupted by Late-Emerging Side Effects of Cancer Treatment
September 9th 2017Side effects that arise months or years after adolescents and young adults (AYAs) have completed cancer treatment — known as late effects — can significantly affect both careers and quality of life in this population.
Conmana Bests Chemotherapy in Progression-Free Survival for Lung Cancer
September 8th 2017According to the results of a recent study conducted in China, patients with stage 3B/4 non-small cell lung cancer (NSCLC) saw a 3.3-month increase in median progression-free survival (PFS) when taking Conmana (icotinib) compared to those who were taking chemotherapy.
FDA Provides an Update on Halted Myeloma Trials
September 7th 2017The Food and Drug Administration (FDA) recently released a statement providing data from the two phase 3 trials testing Keytruda (pembrolizumab) in patients with multiple myeloma. The trials were placed on clinical holds by the FDA in July, after concerns arose regarding the drug’s safety in this group of patients.
Putting Ovarian Self-Awareness in Action with Bright Pink
September 6th 2017September is Ovarian Cancer Awareness Month, but many people still aren’t aware of the symptoms and risk factors that can sometimes lead to an ovarian cancer diagnosis. Here are two steps you can take to personalize your approach to ovarian health management by being "ovarian self-aware."
Keytruda Shows Benefit in Small Cell Lung Cancer
September 6th 2017The immunotherapy agent Keytruda (pembrolizumab) had an overall response rate (ORR) of 33 percent in a recent trial including patients with extensive-stage small cell lung cancer (SCLC). Findings of the phase 1b KEYNOTE-028 trial were published in the Journal of Clinical Oncology.